MSD today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the use of REMICADE® in the treatment of severely active ulcerative colitis in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who ...